scancell.co.uk Report : Visit Site

Technical data of the scancell.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host scancell.co.uk. Currently, hosted in United Kingdom and its service provider is Rackspace Ltd. .

the related websites

calculuscapital.com stockmarketwire.com lse.co.uk bristolmaid.com oxfordtechnology.com digitallook.com investorsoiree.co.uk netdoctor.co.uk fedup.com.au bbc.co.uk esmo.org bbc.com cancerhaircare.com telegraph.co.uk hazards.org 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

menu home company overview board of directors management career opportunities partnerships products cancer vaccine: scib1 product pipeline technology immunobody® vaccines moditope® scientific papers posters investors company profile advisors corporate governance documents & presentations share info financial info regulatory news news latest news 8mg higher dose scib1 study on track moditope patent published scib1 granted fda orphan drug status nottingham technology grant immunobody technology used in prostate cancer protein discovery dna immunobody patent granted in japan new data for scib1 in metastatic melanoma extension to ichor option and issue of equity notice of agm investor update showcases moditope® platform and updates scib1 trial progress investor day agenda investor day dna ib patent in australia frankfurt listing scib1 8mg study update scancell welcomes new study in the journal of clinical investigation immunobody patent approved for grant in japan update on patient recruitment in the ongoing scib1 clinical trial scib1 trial update – higher dose allowed in phase 1/2 trial update on scib1 phase 1/2 clinical trial stimulation of killer cd4 t cells with potent anti-tumour activity scib trial update - approval to dose patients for up to 5 years scib1: first patient treated in phase ii clinical trial scib1 trial update holdings in company investor presentation 2012 immunobody® patent approved in us helium special situations increases interest in scancell confirmation of second tranche payment of £2.85 million from arana therapeutics progress on possible second tranche payment from arana therapeutics scib1: patent awarded scib1: safety review and dose escalation scancell develops new vaccine for the treatment of lung cancer change of board structure scib1: safety review and dose escalation 2011 re: scib1 clinical trial patient recruitment collaboration with immuneregen biosciences® yields positive results in cancer vaccine studies appointment of coo antibody licence agreement with cancer research technology withdrawal from plus and admission to aim research collaboration with immatics to develop novel immunobody® vaccines for colorectal cancer scib1 phase i trial commences scancell enters strategic collaboration with immuneregen biosciences® national institutes of health licensing agreement clinical trial approval for scib1 melanoma vaccine study scancell selects pharmanet development group for scib1 clinical trial completion of gmp manufacture for scancell’s scib1 clinical trial scancell partners with immunovaccine technologies to advance dna vaccine delivery scancell licenses trigrid™ electroporation device from ichor medical systems scancell licenses key immunobody® patents from merck serono scancell receives gbp250,000 emda grant gmp manufacture deal with cobra admission to plus and start of trading reports and accounts april 2008 scancell sells antibody pipeline to peptech gtc biotherapeutics and scancell collaborate on sc101 antibody scancell raises £1.0 million in rights issue scancell signs new agreement with biovation to deimmunise sc101 scancell secures exclusive worldwide licence agreement scancell raises £1.3 million ($2.34m; €2m) in new funding round scancell appoints dr michael capaldi as ceo scancell, onyvax and crt announce agreement to facilitate the development of "immunobody" scancell and celltech announce that they will collaborate on the development of novel monoclonal scancell and isu chemical announce collaboration and licensing agreement for scancell's antibody genmab and scancell announce cancer antibody product collaboration — first disease target identified advances in cancer research webinar collaboration with karolinska scancell’s scib1 immunobody® cancer vaccine being presented at the world vaccine congress citrullination – linking cancer and autoimmunity? scancell to present at the 23rd annual newsmakers in the biotech industry conference in nyc europe patent release commentary: richard goodfellow. why we want to work with patient advocacy groups professor lindy durrant included in top 50 movers and shakers in biobusiness 2017 scancell to acquire novel platform technology from the university of nottingham webcasts, interviews and media coverage archived webcasts and interviews search close search using immunology to fight cancer read more in phase 1/2 clinical trials for the treatment of patients with metastatic melanoma read more novel vaccine platform that destroys tumours read more cancer immunotherapy scib1 immunobody® moditope® cancer immunotherapy cancer remains one of the world’s most significant diseases. a key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer. the company, which was founded in 1997 as a spin-out from the university of nottingham, has secured £23 million funding to date. in december 2006 scancell sold its pipeline of direct killing monoclonal antibodies to arana therapeutics, an australian biopharmaceutical company. the deal allowed scancell to focus its efforts entirely on its innovative immunobody ® and moditope ® cancer vaccine programmes. read more presentation scancell investor presentation, february 16 2018 if you wish to see the full unedited version of this presentation please click here follow scancell on twitter to read our industry commentary and hear our latest news first. follow on twitter scancell holdings plc is an aim listed company latest share price news read all pdmr dealing 25 th july 2018 read issue of equity to ichor 24 th july 2018 read scancell exercises trigrid worldwide commercial option from ichor 18 th july 2018 read webcasts, interviews and media coverage view all scancell holdings inks drug delivery technology deal it has exercised an option on trigrid, which was developed by ichor medical systems wed, 18 jul 2018 06:09:00 scancell receives european patent protection for immunotherapy platform the patent protects a new class of cancer vaccines rolling off the moditope platform wed, 23 may 2018 05:28:00 scancell to raise up to £8mln to develop its three main drug candidates cliff holloway, chief executive at scancell holdings plc (lonsclp), tells proactive investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates. a placing and subscription at 12 pence a share will account for £6mln of the total. the company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded. wed, 18 apr 2018 12:18:00 company overview board of directors management careers partnerships products cancer vaccine scib1 product pipeline technology immunobody® vaccines moditope® scientific papers investors company profile advisors corporate governance company documents share price financial information regulatory news news latest news press releases news updates sign up to our newsletter to stay up to date with scancell email sign up get in touch for more information contact us privacy & legal notes © copyright scancell limited 2018 a site by the unified theory menu home company overview board of directors management career opportunities partnerships products cancer vaccine: scib1 product pipeline technology immunobody® vaccines moditope® scientific papers posters investors company profile advisors corporate governance documents & presentations share info financial info regulatory news news latest news 8mg higher dose scib1 study on track moditope patent published scib1 granted fda orphan drug status nottingham technology grant immunobody technology used in prostate cancer protein discovery dna immunobody patent granted in japan new data for scib1 in metastatic melanoma extension to ichor

URL analysis for scancell.co.uk

http://www.scancell.co.uk/news/latest-news/citrullination-linking-cancer-and-autoimmunity
http://www.scancell.co.uk/news/latest-news/withdrawal-from-plus-and-admission-to-aim
http://www.scancell.co.uk/news/latest-news/collaboration-with-karolinska
http://www.scancell.co.uk/news/latest-news/europe-patent-release
http://www.scancell.co.uk/news/latest-news/scancell-selects-pharmanet-development-group-for-scib1-clinical-trial
http://www.scancell.co.uk/technology/moditope
http://www.scancell.co.uk/news/latest-news/investor-day
http://www.scancell.co.uk/news/latest-news/antibody-licence-agreement-with-cancer-research-technology
http://www.scancell.co.uk/news/latest-news/scib-trial-update-approval-to-dose-patients-for-up-to-5-years
http://www.scancell.co.uk/company/career-opportunities
http://www.scancell.co.uk/news/latest-news/scancell-receives-gbp250000-emda-grant
http://www.scancell.co.uk/news/latest-news/national-institutes-of-health-licensing-agreement
http://www.scancell.co.uk/news/latest-news/scancell-welcomes-new-study-in-the-journal-of-clinical-investigation
http://www.scancell.co.uk/company/overview
http://www.scancell.co.uk/news/latest-news/gmp-manufacture-deal-with-cobra
theunifiedtheory.co.uk
proactiveinvestors.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "scancell.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 223 seconds

WHOIS lookup made at 11:08:44 23-Aug-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS scancell.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME scancell.co.uk

NSERVER

  NS.MAINNAMESERVER.COM 79.170.40.2

  NS2.MAINNAMESERVER.COM 79.170.43.3

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .